Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case-control study

Yael N Kusne; Heidi E Kosiorek; Matthew R Buras; Patricia M Verona; Kyle E Coppola; Kelley A Rone; Curtiss B Cook; Nina J Karlin

doi:10.2144/fsoa-2020-0190

Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case-control study

Future Sci OA. 2021 Feb 15;7(5):FSO684. doi: 10.2144/fsoa-2020-0190.

Authors

Yael N Kusne¹, Heidi E Kosiorek², Matthew R Buras², Patricia M Verona³, Kyle E Coppola⁴, Kelley A Rone⁵, Curtiss B Cook⁶, Nina J Karlin^{4

5}

Affiliations

¹ Department of Internal Medicine, Mayo Clinic, Scottsdale 85259, Arizona.
² Biostatistics, Mayo Clinic, Scottsdale 85259, Arizona.
³ Enterprise Technology Services, Mayo Clinic, Scottsdale 85259, Arizona.
⁴ Mayo Clinic Cancer Center, Mayo Clinic, Scottsdale 85259, Arizona.
⁵ Division of Hematology & Medical Oncology, Mayo Clinic Hospital, Phoenix 85054, Arizona.
⁶ Division of Endocrinology, Mayo Clinic, Scottsdale 85259, Arizona.

Abstract

Aim: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control.

Patients & methods: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005-2017), and survival compared (Kaplan-Meier and Cox proportional hazards). Mixed models compared hemoglobin A_1c (HbA_1c) and glucose during the year after cancer diagnosis.

Results: Three-year overall survival was 72% (95% CI: 60-86%) for DM patients versus 80% (95% CI: 70-92%) for non-DM patients (p = 0.82). Hazard ratio was 1.33 (95% CI: 0.56-3.16; p = 0.51); mean DM HbA_1c, 7.3%.

Conclusion: DM did not adversely affect survival of patients with NET. NET and its treatment did not affect glycemic control.

Keywords: cancer; endocrinology; prognostics.